ATLANTA, March 31, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company”), a development-stage biotechnology company developing new medicines to treat pain and ...
Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining attention as it advances TNX-102 SL, a non-opioid investigational therapy for fibromyalgia, toward po ...
Lady Gaga has been open about her health struggles over the years and in 2017, she shared that she had been diagnosed with ...
Morgan Freeman, 87, has been living with fibromyalgia, a painful condition, following a 2008 car crash that left him severely ...
A Jordanian study finds that over one-third of women with lupus suffer from depression, and nearly one-third have ...
Clifton was diagnosed with anxiety and depression as a teen. She used her mental diagnoses and her physical diagnosis; ...
Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.
Some forms of exercise training and pharmacological-based interventions may improve fibromyalgia-related sleep disturbances, though evidence is limited.
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.
Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results